Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.59 |
| ▸ | PNMT | P11086 | 8/20 | 0.51 |
| ▸ | CD44 | P16070 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16518079 | 0.85 | PRCP (0.61) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL3052029 | 0.83 | PNMT (0.61) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518132 | 0.83 | PRCP (0.58) | PRCPPNMTCD44MAOBADRA2A | |
| Hydrochloric Acid SCHEMBL2258194 | 0.81 | PNMT (0.59) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518127 | 0.80 | PRCP (0.55) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518136 | 0.79 | PNMT (0.62) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518137 | 0.79 | PRCP (0.54) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518022 | 0.78 | PRCP (0.56) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518140 | 0.78 | PRCP (0.52) | PRCPPNMTCD44MAOBADRA2A | |
| SCHEMBL16518130 | 0.78 | PNMT (0.53) | PRCPPNMTADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671869-B1 | TETRAHYDROISOQUINOLINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2671869-B1 | TETRAHYDROISOQUINOLINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2015-11-04 | — | — | EP | disclosed |
| CN-103339109-B | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC | 2015-04-29 | — | — | CN | disclosed |
| US-8962612-B2 | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8962612-B2 | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8962612-B2 | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-2671869-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130317010-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2013-11-28 | — | — | US | disclosed |
| CN-103339109-A | Tetrahydroisoquinoline derivative | ASTELLAS PHARMA INC | 2013-10-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317010-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE | HTR5A, HTR2A, HTR1A | PRCP 4326/4885PNMT 219/4885CD44 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.